

Nitric oxide metabolites (nitrite and nitrate) in several clinical condition

G. Caimi*, E. Hopps, M. Montana, C. Carollo, V. Calandrino, E. Incalcaterra, B. Canino and R. Lo Presti

Dipartimento Biomedico di Medicina Interna e Specialistica, Università di Palermo, Palermo, Italy

Abstract. We determined the concentration of nitric oxide metabolites ($\text{NO}_2^- + \text{NO}_3^-$), expressed as NOx, in several clinical conditions. Regarding this, we have examined 25 subjects with arterial hypertension, 41 subjects with chronic kidney disease in conservative treatment, 106 subjects with metabolic syndrome subdivided according to the presence ($n=43$) or not ($n=63$) of diabetes mellitus, 48 subjects with obstructive sleep apnea syndrome (OSAS), 14 women with systemic sclerosis complicated with Raynaud's phenomenon, 42 dialyzed subjects and 105 young subjects with acute myocardial infarction (AMI). In subjects with arterial hypertension, chronic kidney disease, metabolic syndrome, systemic sclerosis, as well as, in dialyzed and AMI subjects, we found at baseline a NOx increase. In dialyzed subjects after a standard dialysis session, we observed a decrease in NOx. The increase in NOx in juvenile AMI was significantly influenced by cigarette smoking and less by cardiovascular risk factors and the extent of coronary lesions; at 3 and 12 months later than the initial event, we observed a decrease of NOx that remains significantly higher than the control group. In subjects with OSAS no difference in NOx was noted in comparison with normal controls, although their subdivision according to the apnea/hypopnea index operates a clear distinction regarding NOx concentration.

Keywords:

1. Introduction

Even if, at baseline, the main origin of plasma nitric oxide (NO) seems to be related to endothelial nitric oxide synthase (eNOS), in several clinical conditions the inducible NOS (iNOS) is hyperactivated and this event is especially associated with the increase of cytokines such as $\text{TNF}\alpha$, $\text{IL-1}\beta$ and interferon [29, 56, 75]. As it is known NO is produced through the oxidation of L-arginine in different cells by a family of enzymes, the nitric oxide synthases, subdivided in three major classes: neuronal-NOS (nNOS, type I), inducible-NOS (iNOS, type II) and endothelial-NOS (eNOS, type III). Each isoform is encoded on a different chromosome: the nNOS is encoded on chromosome 12, the iNOS on chromosome 17 while the eNOS on chromosome 7. The biological activity of each isoform depends on different conditions, in fact the synthesis and activity of eNOS and nNOS requires calcium and calmodulin while the iNOS activity is decreased by glucocorticoids and increased by proinflammatory cytokines. The activation of iNOS generates NO in the measure of up 1000-fold greater than nNOS or eNOS [57] it has also been demonstrated that the more important modulators of these proinflammatory cytokines are the mitogen activated protein kinases [32]. This accelerated NO synthesis has however an opposite effect because

*Corresponding author: Prof. Gregorio Caimi, Dipartimento Biomedico di Medicina Interna e Specialistica, Università di Palermo, Via del Vespro, 129 90100 Palermo, Italy. Tel.: +39 0916554406; Fax: +39 091 6554535; E-mail: gregorio.caimi@unipa.it.

NO interacts with the superoxide anion (O_2^-) to produce peroxynitrite and other oxidants involved in tissue injury. Considering this pathophysiological aspect, NOS inhibitors have been administered in some critical conditions, such as congestive heart failure [64], refractory cardiogenic shock [21], cardiogenic shock complicating an acute myocardial infarction [26, 58, 70] and septic shock [44]. Among the NOS inhibitors, the L-monomethylarginine (L-NMM), a non-selective NOS inhibitor, has been investigated the most. The TRIUMPH study [70] has been conducted in 130 centers and in 8 countries in North America and Europe, enrolling 398 patients with acute myocardial infarction (AMI) and cardiogenic shock; it has demonstrated, however, that the use of tilarginine acetate has no effect on mortality of these patients. Other authors [65] have consequently suggested avoiding further trials with non-selective inhibitors of NOS in the cardiovascular area. Whereas the considerations about the possible coming of NO are interesting. As it is known, NO metabolites, such as nitrite (NO_2^-) and nitrate (NO_3^-), usually evaluated together and expressed as NOx, may play a positive role in stable clinical conditions, because they can be reduced to NO once again [20, 49, 53, 54]. All the NO produced, including those generated by red blood cells subjected to several stimuli, such as mechanical and shear stress [71–73], act on the cardiovascular system contributing to the modulation of blood flow and vascular tone and regulating vascular relaxation without, however, recognizing the pivotal role played in this microcirculatory area by the haemorheological pattern [28, 33].

Considering these information, we examined the behavior of NOx in different clinical conditions, such as arterial hypertension, chronic kidney disease (CKD) on conservative treatment, metabolic syndrome, obstructive sleep apnea syndrome (OSAS), systemic sclerosis, CKD in dialysis treatment and juvenile acute myocardial infarction.

2. Subjects

We examined 7 groups of subjects.

- The first group included 25 subjects (19 men and 6 women; mean age 44.4 ± 7.7 yrs) with untreated mild essential hypertension. In this group hypertension duration was of 19.3 ± 32.8 months, fasting blood glucose was 91.4 ± 10.9 mg/dl, cholesterol level was 210.0 ± 37.0 mg/dl, HDL-chol was 44.41 ± 8.19 mg/dl, triglycerides were 101.1 ± 7.8 mg/dl, and serum uric acid was 5.74 ± 1.63 mg/dl. In hypertensives the body mass index (BMI) was 26.6 ± 3.5 and the waist to hip ratio (WHR) was 0.91 ± 0.05 , while day-time systolic (S) and diastolic (D) blood pressure (BP) were respectively 133.80 ± 8.12 and 86.05 ± 6.79 mmHg, night-time SBP and DBP were respectively 120.40 ± 10.86 and 75.00 ± 7.65 mmHg and the 24-h SBP and DBP were respectively 128.00 ± 8.50 and 81.73 ± 6.36 mmHg. This group was compared with a control group including 27 healthy subjects (20 men and 7 women; mean age 41.3 ± 6.2 yrs).
- The second group included 41 subjects (25 men and 16 women; mean age 64.7 ± 11.1 yrs) with clinically stable CKD on conservative management. The causes of CKD were chronic pyelonephritis in 9 subjects, nephroangiosclerosis in 6, chronic pyelonephritis associated with nephroangiosclerosis in 8, chronic glomerulonephritis in 5, diabetic nephropathy in 8 and polycystic kidney disease in 5. In this group serum creatinine was 3.05 ± 1.79 mg/dl, creatinine clearance was 28.56 ± 17.13 ml/min, haemoglobin level was 12.2 ± 2.1 g/dl. The CKD subjects were subdivided according to age in two subgroups: 22 subjects <65 yrs and 19 subjects ≥ 65 yrs. This group was compared with a control group including 51 healthy subjects (39 men and 12 women; age range 24–60 yrs).

- 72 – The third group included 106 subjects (61 men and 45 women; mean age 53.5 ± 8.9 yrs) with
73 metabolic syndrome (MS) defined according the International Diabetes Federation (IDF) criteria [3].
74 In this group BMI was 32.32 ± 4.53 , waist circumference was 106.7 ± 11.2 cm, SBP and DBP were
75 respectively 132.1 ± 16.3 and 81.2 ± 9.9 mmHg, fasting blood glucose was 114.3 ± 44.3 mg/dl, HDL-
76 chol was 40.4 ± 10.8 mg/dl and triglycerides were 220.2 ± 147.8 mg/dl. This group was compared
77 with a control group including 54 healthy subjects (35 men and 19 women; mean age 41.3 ± 7.4 yrs)
78 recruited from the hospital staff.
- 79 – The fourth group included 48 subjects (36 men and 12 women; mean age 50.3 ± 14.68 yrs) with
80 OSAS. In this group BMI was 35.46 ± 7.28 , waist circumference was 118.75 ± 15.88 cm, neck
81 circumference was 44.4 ± 4.77 cm, and the apnea/hypopnea index (AHI) was 38.47 ± 25.39 . OSAS
82 subjects were subdivided according to the AHI value in two subgroups: Low (21 subjects with AHI
83 <30) and High (27 subjects with AHI >30). This group was compared with a control group including
84 54 healthy subjects (35 men and 19 women; mean age 41.3 ± 7.4 yrs) recruited from the hospital staff.
- 85 – The fifth group included 14 women (mean age 45.4 ± 5.4 yrs) with systemic sclerosis complicated
86 with Raynaud phenomenon. In these patients the duration of the disease was 3.1 ± 2.0 yrs; each
87 patient showed skin disease, 3 subjects had esophageal disease, 2 subjects had pulmonary alterations
88 and 1 subject showed renal damage. Immunological alterations (ANA, anti-Scl, anti SSA) were
89 demonstrated in 12 women. This group was compared with a control group including 12 healthy
90 women (mean age 35.1 ± 6.5 yrs).
- 91 – The sixth group included 42 dialyzed subjects (21 men and 21 women; mean age 66.83 ± 14.8
92 yrs). The cause of CKD was unknown in 12 subjects, nephroangiosclerosis was demonstrated in
93 12, chronic glomerulonephritis in 4, diabetic nephropathy in 10 and polycystic kidney disease in
94 4. Dialysis vintage in the whole group was 55.3 ± 43.5 months. In this group the behavior of NOx
95 was evaluated before and after a standard hemodialysis session. This group was compared with a
96 control group including 51 healthy subjects (39 men and 12 women; age range 24–60 yrs).
- 97 – The seventh group included 105 young subjects (97 men and 8 women, aged <46 yrs) with recent
98 AMI. The mean age was 39.6 ± 5.5 yrs. The time interval between AMI onset and the evaluation
99 of NOx was 13.0 ± 7.0 days. AMI subjects were subdivided according to the number of risk
100 factors (family history of coronary artery diseases, smoke, hypercholesterolemia, diabetes mellitus,
101 essential hypertension) into 3 subgroups: 38 subjects had 0 to 1 risk factor, 35 had 2 risk factors and
102 32 had 3 to 5 risk factors. On the basis of coronary angiography (performed only in 92 subjects),
103 AMI subjects were subdivided into 3 subgroups considering the extent of coronary lesions: 21
104 subjects showed no significant lesions, 1-vessel disease was present in 41 subjects and 2- or 3-vessel
105 disease was observed in 30 subjects. This group was compared with a control group including 51
106 healthy subjects (39 men and 12 women; age range 24–60 yrs).

107 3. Methods

108 On fasting venous blood the NO production was evaluated by a micromethod which measures the
109 concentration of NO metabolites: nitrite and nitrate (NOx). *In vivo* NO has a very short life (less than
110 0.1 sec) and it is converted into nitrite (NO_2^-), which has a half-life of few minutes, and into the more
111 stable nitrate (NO_3^-). Then NOx represents almost only the nitrate concentration. In the laboratory
112 method adopted by us at first nitrate was converted into nitrite by a nitrate reductase and then nitrite was
assessed by spectrophotometry after addition of Griess reagent.

4. Statistical analysis

Data were expressed as means \pm S.D.; the difference between normal subjects (N) and each group of patients was evaluated according to the Student's t test for unpaired data. The statistical difference between control subjects and subjects with MS subdivided according to the presence or not of diabetes mellitus was estimated according to the 1-way analysis of variance (ANOVA) integrated with the Bonferroni test. Same statistical approach was used for the examination of OSAS subjects subdivided according to the AHI value and for the examination of AMI subjects, subdivided according to risk factors and extension of coronary lesions. The evaluation of NOx before and after dialysis was effected using the Student's t test for paired data; same approach was employed to evaluate NOx before and after treatment with intravenous iloprost in subjects with systemic sclerosis and to evaluate NOx at the initial stage of AMI and 3 and 12 months later. The correlations were performed employing the linear regression test. The null hypothesis was rejected for p values <0.05 .

5. Results

The obtained data are described for each clinical condition.

5.1. Arterial hypertension

In this group of subjects with mild essential hypertension (EH) we observed [15] a significant increase in NOx ($N = 28.36 \pm 18.36$; $EH = 48.78 \pm 23.17$, $p < 0.001$). The NOx was not related to metabolic parameters (fasting glucose level, lipid pattern, uric acid, urea, creatinine), to BMI and WHR or to the blood pressure values (day-time, night-time and 24-h systolic and diastolic blood pressure).

5.2. Chronic kidney disease

In this group of CKD on conservative treatment we found [12] a significant rise in NOx ($N = 24.38 \pm 15.67$; $CKD = 74.19 \pm 69.05$, $p < 0.001$). In this group no correlation was noted between NOx, creatinine level and creatinine clearance. The subdivision of these subjects according to age did not show any difference (data not shown).

5.3. Metabolic syndrome

In this group of subjects with MS, we observed [13] a significant increment in NOx ($N = 28.07 \pm 18.83$; $MS = 79.82 \pm 29.22$, $p < 0.001$). This finding was also present between normal subjects and MS subjects with diabetes mellitus ($N = 28.07 \pm 18.83$; $DMS = 78.10 \pm 20.76$, $p < 0.001$) and between normal subjects and MS subjects without diabetes mellitus ($N = 28.07 \pm 18.83$; $NDMS = 80.99 \pm 33.93$, $p < 0.001$). Testing the linear regression between NOx, age, anthropometric profile, blood pressure values and glycometabolic pattern, we found a positive correlation between NOx and triglycerides ($r = 0.344$, $p < 0.001$) in the whole group of MS subjects, a positive correlation between NOx and total cholesterol ($r = 0.442$, $p < 0.01$) and between NOx and LDL-cholesterol ($r = 0.441$, $p < 0.01$) in the subgroup of diabetic subjects ($N = 43$), and a positive correlation between NOx and triglycerides ($r = 0.43$, $p < 0.001$) while a negative correlation between NOx and HDL-cholesterol ($r = -0.287$, $p < 0.05$) in the subgroup of nondiabetic subjects ($N = 63$).

148 5.4. OSAS

149 In this group of subjects no statistical difference in NOx was observed in comparison with normal
150 controls ($N = 28.07 \pm 18.83$; OSAS = 27.49 ± 10.13). However, subdividing the whole group of OSAS
151 according to AHI value in two subgroups (Low: AHI <30, High: AHI >30), we noted a slight decrease of
152 NOx in the subgroup with AHI >30 in comparison with the subgroup with AHI <30 ($H = 22.84 \pm 7.64$;
153 $L = 33.47 \pm 10.05$, $p < 0.05$), but not with normal controls. We found a negative correlation between NOx
154 and AHI in the whole group of OSAS subjects ($r = -0.615$, $p < 0.001$), in the subgroup with low AHI
155 ($r = -0.490$, $p < 0.05$) and also in the subgroup with high AHI ($r = -0.413$, $p < 0.05$).

156 5.5. Systemic sclerosis

157 In this group of subjects with systemic sclerosis (SS) complicated by Raynaud phenomenon, we
158 observed [47] a slight increase in NOx ($N = 23.26 \pm 16.11$; SS = 37.77 ± 18.46 , $p < 0.05$). After a short
159 treatment with intravenous iloprost (0.5 to 2 ng/kg/min, 6 hours/die for 5 consecutive days and, after an
160 interval of 2 days, for another 5 consecutive days) we noted a marked increase in NOx concentration
161 (before iloprost = 37.77 ± 18.46 ; after iloprost = 61.19 ± 28.79 , $p < 0.05$).

162 5.6. Dialyzed subjects

163 In this group of dialyzed subjects (DS) we found [11, 45] a significant increase in NOx ($N = 24.38 \pm 15$;
164 DS = 69.20 ± 35.33 , $p < 0.001$). The subdivision of DS according to dialysis vintage did not show any
165 difference in NOx concentration (data not shown). The trend of NOx before and after a standard
166 hemodialysis session showed instead a significant decrease of this parameter (before = 69.20 ± 35.33 ;
167 after = 26.80 ± 17.80 , $p < 0.001$). During the dialysis session, the employment of different filters did not
168 influence the NOx behavior (data not shown).

169 5.7. Acute myocardial infarction

170 In this group of young subjects with AMI we found [46] a significant increase in NOx
171 ($N = 24.38 \pm 15.67$; AMI = 64.47 ± 31.90 , $p < 0.001$). Subdividing AMI subjects into smokers and
172 nonsmokers, we noted that NOx was significantly lower in nonsmokers (smokers = 70.91 ± 33.38 ; non-
173 smokers = 50.85 ± 15.31 , $p < 0.05$). Subdividing AMI subjects according to the number of risk factors or
174 of stenosed coronary vessels, no significant difference in NOx concentration between the subgroups was
175 observed. In 55 AMI subjects NOx was evaluated at the initial stage and after 12 months and it showed
176 a significant decrease (initial stage = 69.33 ± 27.38 ; 12 months = 37.71 ± 17.29 , $p < 0.001$). In a small
177 group of AMI subjects (38 men and 5 women) we evaluated [14] the trend of NOx at the initial stage
178 (T1), after 3 months (T2) and after 12 months (T3) observing its progressive decrease (T1 = 70.14 ± 26.70 ,
179 T2 = 56.70 ± 23.87 , T3 = 37.27 ± 18.96).

180 6. Conclusive consideration

181 Our finding on mild essential hypertension points out a significant NOx increase. As in this clinical
182 condition several inflammatory molecules seem to be released, this datum might be related to a NO

183 overproduction by macrophages through iNOS activation. However, it must be underlined that this finding,
184 that is in agreement with those of few authors [60, 79], conflicts with the observations of others [6, 38,
185 39, 74]. Considering this latter remark, it is not possible to exclude, as far as the NOx concentration is
186 concerned, the role played in this cardiovascular disease by impaired microvascular function, that can
187 later progress into capillary rarefaction, as has been clearly demonstrated previously by several studies
188 [19, 22, 27, 37]. This microvascular alteration perhaps is not present in subjects with mild essential
189 hypertension.

190 The findings observed in CKD on conservative treatment and in dialyzed subjects need to be examined
191 together. In these two groups, in fact, the increase in NOx, described also by other authors [36], may be
192 explained by impairment of renal excretion [50] or by macrophage NO synthesis. This latter hypothesis
193 deserves to be underlined considering the role played by asymmetric dimethylarginine (ADMA) in CKD
194 [10]. As it is known, in fact, ADMA removal is blocked in CKD subjects leading to high plasma levels
195 of this inhibitor of all NOS isoforms [48]. Regarding the trend of NOx before and after dialysis session,
196 we observed a significant decrease in NOx after dialysis as did other authors [78], although Zhang et
197 al. have found a NOx increase [80]. This discrepancy regarding the trend of NOx after dialysis must be
198 further developed.

199 In MS subjects a NOx increase was observed and this finding was similar in the two subgroups of
200 diabetic and nondiabetic subjects. These data agree with the observations of others who studied NOx in
201 MS or in its components [7, 8, 15, 17, 35, 36, 60, 62, 63, 79]. Our results show in diabetic MS subjects
202 a positive correlation between NOx and total cholesterol and LDL-cholesterol while in nondiabetic
203 subjects a negative correlation between NOx and HDL-cholesterol. The literary data do not confirm
204 these findings in healthy adult subjects [31] or in overweight and obese women [59] while in adolescents
205 NOx has been correlated positively to the total cholesterol and LDL-cholesterol and negatively to HDL-
206 cholesterol [18]. We observed a positive correlation between NOx and triglycerides in the entire group
207 of MS subjects and in the subgroup of nondiabetics. This datum, in agreement with those described by
208 others in postmenopausal MS women [16], in adolescents [18] and in a general healthy population [31],
209 is different from that observed [24] in subjects with normal-weight obese syndrome.

210 The behavior of NOx in subjects with OSAS is interesting. This is confirmed by some authors [23], but
211 conflicts with other papers [40, 66]; the subdivision of these subjects according to AHI shows a marked
212 decrease in NOx in the subgroup with AHI >30. Agreeing with other authors [30], in the entire group
213 and in the two subgroups of OSAS we found a negative correlation between NOx and AHI. Another
214 interesting finding is the positive correlation between AHI and neck circumference observed in entire
215 group ($r=0.60$, $p<0.001$) and in the subgroup with AHI <30 ($r=0.55$, $p<0.05$). Later we will examine,
216 especially in OSAS subjects with AHI >30, the trend of NOx after treatment with continuous positive
217 airway pressure (cPAP); some papers have in fact described a NOx increase after therapy with cPAP [40,
218 61, 66], differently from others [23].

219 In subjects with systemic sclerosis complicated by Raynaud's phenomenon we observed a NOx increase
220 and this datum is entirely in agreement with those of some authors [25, 55, 69, 77] but partially with
221 those of others who described only a nitrite (NO_2^-) increase [61] or a nitrate increase (NO_3^-) [5]. Other
222 authors [4, 52] however, found a NOx decrease in this clinical condition. In the paper of Takagi et al
223 [69] NOx level was positively correlated with some clinical features, such as the extent of skin fibrosis,
224 short disease duration and active fibrosing alveolitis. In a subgroup of subjects with systemic sclerosis
225 examined by Mok et al [55] a positive correlation between NOx and pulmonary arterial pressure was
226 found and prednisolone treatment was associated with decreased NOx. In our small group of subjects
227 with systemic sclerosis the venous infusion of iloprost increases significantly the value of NOx. This

228 finding is different from that observed by others [51] in 29 subjects with chronic peripheral ischaemia (15
229 suffering from systemic sclerosis); in this group in fact iloprost infusion enhances microvascular function
230 with clinical benefits but without any NO_x variation.

231 In young subjects with AMI we found a marked increase in NO_x, in agreement with other authors [68]. As
232 it is known, during the acute phase of AMI, iNOS activity increases as a reaction to the high oxidative stress
233 [76]. In experimental models the ligation of the left anterior descending coronary artery was associated
234 with NO_x increase, which reached a peak after 3 days [2]. The same behavior of NO_x has been observed
235 in a small group of subjects with anterior myocardial infarction examined at 24, 48 and 72 hours after the
236 event [1]. In this research the NO_x peak occurred 2 or 3 days after the onset of symptoms, suggesting that
237 NO_x increase was correlated with iNOS activation induced especially by cytokines. In our study [14, 46]
238 NO_x was significantly reduced in nonsmokers and that its trend was conditioned more by cardiovascular
239 risk factors than by the extent of coronary lesions. At 3 and 12 months we observed a progressive decrease
240 of NO_x, remaining at both times significantly higher than the control group. The persistent increase in
241 NO_x could be a further confirmation of a chronic inflammatory state, that might be related to the genetic
242 profile of these subjects, showing in many cases pro-inflammatory alleles [9, 34, 41–43].

243 In conclusion, the data described seem to point out a role of iNOS activation in almost all the clinical
244 conditions considered. The iNOS activity is stimulated in particular by pro-inflammatory cytokines and
245 by oxidative stress, which is evident in each group of patients studied by us as increased lipid peroxidation
246 and protein oxidation and decreased total antioxidant status. Then it is possible to suppose that the NO_x
247 increase found in arterial hypertension, chronic kidney disease, metabolic syndrome, systemic sclerosis
248 and juvenile myocardial infarction can reflect this hyperactivation. Whereas the behavior of NO_x in OSAS
249 subjects needs further investigation. Its trend, in fact, depends on OSAS severity expressed as AHI. The
250 subdivision of OSAS subjects according to this index allows the discrimination of two subgroups and
251 the demonstration that in the subgroup with AHI >30 the NO_x value is significantly lower than in the
252 subgroup with AHI <30. It is not possible to exclude that this behavior might depend, through the nocturnal
253 hypoxemia, on the altered balance between NO_x synthesis and NO_x removal and this hypothesis seems
254 to be supported by the increase in NO_x value after cPAP therapy.

255 References

- 256 [1] K. Akiyama, A. Kimura, H. Suzuki, Y. Takeyama, T.L. Gluckman, A. Terhakopian, T. Katagiri, K.Y. Suh, J. Roseto and
257 R.J. Ring, Production of oxidative products of nitric oxide in infarcted human heart, *Journal of Molecular and Cellular*
258 *Cardiology* **32** (1998), 373–379.
- 259 [2] K. Akiyama, H. Suzuki, P. Grant and R.J. Bing, Oxidant products of nitric oxide, NO₂ and NO₃, in plasma after experimental
260 myocardial infarction, *Journal of Molecular and Cellular Cardiology* **29** (1997), 1–9.
- 261 [3] K.G. Alberti, P. Zimmet and J. Shaw, Metabolic syndrome – a new world-wide definition. A Consensus Statement from
262 the International Diabetes Federation, *Diabetic Medicine* **23** (2006), 469–480.
- 263 [4] Y. Allanore, D. Borderie, P. Hilliguin, A. Nernvann, M. Levacher, H. Lemarechal, O.G. Ekindjian and A. Kahan, Low
264 levels of nitric oxide (NO) in systemic sclerosis: Inducible NO synthase production is decreased in cultured peripheral
265 blood monocyte/macrophage cells, *Rheumatology (Oxford)* **40** (2001), 1089–1096.
- 266 [5] G.N. Andersen, K. Caidahl, E. Kazzam, A.S. Petersson, A. Waldenstrom, L. Mincheva-Nilsson and S. Rantapaa-Dahlqvist,
267 Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis, *Arthritis*
268 *& Rheumatism* **43** (2000), 1085–1093.
- 269 [6] M.C. Armas-Padilla, M.J. Armas-Hernandez, B. Sosa-Chanache, R. Cammarata, B. Pacheco, J. Guerrero, A.R. Carvajal, R.
270 Hernandez-Hernandez, Z.H. Israili and M. Valasco, Nitric oxide and malondialdehyde, *American Journal of Therapeutics*
271 **14** (2007), 172–176.

- 272 [7] S.Z. Asl, A. Ghasemi and F. Azizi, Serum nitric oxide metabolites in subjects with metabolic syndrome, *Clinical Biochem-*
273 *istry* **41** (2008), 1342–1347.
- 274 [8] A. Aydin, H. Orhan, A. Sayal, M. Ozata, G. Sahin and A. Isimer, Oxidative stress and nitric oxide related parameters in
275 type II diabetes mellitus: Effects of glycemic control, *Clinical Biochemistry* **34** (2001), 65–70.
- 276 [9] C.R. Balistreri, S. Vasto, F. Listí, M.P. Grimaldi, D. Lio, G. Colonna-Romano, M. Caruso, G. Caimi, E. Hoffman, C.
277 Caruso and G. Candore, Association between +1059G/C CRP polymorphism and acute myocardial infarction in a cohort
278 of patients from Sicily: A pilot study, *Annals of the New York Academy of Science* **1067** (2006), 267–281.
- 279 [10] R.H. Boger and C. Zoccali, ADMA: A novel risk factor that explains excess cardiovascular event rate in patients with
280 end-stage renal disease, *Atherosclerosis* **4** (2003), 23–28.
- 281 [11] G. Caimi, C. Carollo, M. Montana, R. Iatrino, B. Bondí and R. Lo Presti, Nitric oxide metabolites, leukocyte activation
282 markers and oxidative status in dialyzed subjects, *Blood Purification* **27** (2009), 194–198.
- 283 [12] G. Caimi, C. Carollo, M. Montana, F. Vaccaro and R. Lo Presti, Elastase, myeloperoxidase, nitric oxide metabolites and
284 oxidative status in subjects with clinical stable chronic renal failure on conservative treatment, *Clin Hemorheol Microcirc*
285 **43** (2009), 251–256.
- 286 [13] G. Caimi, E. Hopps, M. Montana, D. Noto, B. Canino, R. Lo Presti and M.R. Averna, Evaluation of nitric oxide metabolites
287 in a group of subjects with metabolic syndrome, *Diabetes & Metabolic Syndrome* **6** (2012), 132–135.
- 288 [14] G. Caimi, M. Montana, V. Calandrino, M. Caruso, C. Carollo, A. Catania and R. Lo Presti, Nitric oxide metabolites (nitrite
289 and nitrate) in young patients with recent acute myocardial infarction, *Clin Hemorheol Microcirc* **40** (2008), 157–163.
- 290 [15] G. Caimi, G. Mulè, E. Hopps, C. Carollo and R. Lo Presti, Nitric oxide metabolites and oxidative stress in mild essential
291 hypertension, *Clin Hemorheol Microcirc* **46** (2010), 321–325.
- 292 [16] P. Chedraui, G.S. Escobar, C. Ramirez, F.R. Perez-Lopez, L. Hidalgo, P. Mannella, A. Genazani and T. Simoncini, Nitric
293 oxide and pro-inflammatory cytokine serum levels in postmenopausal women with the metabolic syndrome, *Gynecological*
294 *Endocrinology* **28** (2012), 787–791.
- 295 [17] W.Y. Chien, K.D. Yang, H.L. Eng, Y.H. Hu, P.Y. Lee, S.T. Wang and P.W. Wang, Increased plasma concentration of nitric
296 oxide in type 2 diabetes but not in nondiabetic individuals with insulin resistance, *Diabetes & Metabolism* **31** (2005),
297 63–68.
- 298 [18] J.W. Choi, Enhanced nitric oxide production is closely associated with serum lipid concentrations in adolescents, *Clinica*
299 *Chimica Acta* **347** (2004), 151–156.
- 300 [19] G. Ciuffetti, L. Pasqualini, M. Pirro, R. Lombardini, M. de SIO, G. Schillaci and E. Mannarino, Blood rheology in men
301 with essential hypertension and capillary rarefaction, *Journal of Human Hypertension* **16** (2002), 533–537.
- 302 [20] K. Cosby, K.S. Partovi, J.H. Crawford, R.P. Patel, C.D. Reiter, S. Martyr, B.K. Yang, M.A. Waclawiw, G. Zalos, X. Xu,
303 K.T. Huang, H. Shields, D.B. Kim-Shapiro, A.N. Schecher, R.O. Cannon 3rd and M.T. Gladwin, Nitrite reduction to nitric
304 oxide by deoxyhemoglobin vasodilates the human circulation, *Nature Medicine* **9** (2003), 1498–1505.
- 305 [21] G. Cotter, E. Kaluski, O. Milo, A. Blatt, A. Salah, A. Hendler, R. Krakover, A. Golick and Z. Vered, LINC: L-NAME (a
306 NO synthase inhibitor) in the treatment of refractory cardiogenic shock, *European Heart Journal* **24** (2003), 1287–1295.
- 307 [22] R.T. de Jong, E.H. Sernè, R.G. Ijzerman, G. de Vries and C.D.A. Stehouwer, Impaired microvascular function in Obesity,
308 *Circulation* **109** (2004), 2529–2535.
- 309 [23] M. Del Ben, M. Fabiani, L. Loffredo, L. Polimeni, R. Carnevale, F. Baratta, M. Brunori, F. Albanese, T. Augelletti, F. Violi
310 and F. Angelico, Oxidative stress mediated arterial dysfunction in patients with obstructive sleep apnoea and the effect of
311 continuous positive airway pressure treatment, *BMC Pulmonary Medicine* **12** (2012), 36.
- 312 [24] L. Di Renzo, F. Galvano, C. Orlandi, A. Bianchi, C. Di Giacomo, L. La Fauci, R. Acquaviva and A. De Lorenzo, Oxidative
313 stress in normal-weight obese syndrome, *Obesity* **18** (2010), 2125–2130.
- 314 [25] A. Dooley, B. Gao, N. Bradley, D.J. Abraham, C.M. Black, M. Jacobs and K.R. Burkdorfer, Abnormal nitric oxide
315 metabolism in systemic sclerosis: Increased levels of nitrated proteins and asymmetric dimethylarginine, *Rheumatology*
316 *(Oxford)* **45** (2006), 676–684.
- 317 [26] V. Dzavik, G. Cotter, H.R. Reynolds, J.H. Alexander, K. Ramanathan, A.L. Stebbins, D. Hathaway, M.E. Farkouh, E.M.
318 Ohman, D.A. Baran, R. Prondzinsky, J.A. Panza, W.J. Cantor, Z. Vered, C.E. Buller, N.S. Kleiman, J.G. Webb, D.R.
319 Holmes, J.E. Parrillo, S.L. Hazen, S.S. Gross, R.A. Harrington and J.S. Hochman, Effect of nitric oxide synthase inhibition
320 on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction:
321 A phase II dose-ranging study, *European Heart Journal* **28** (2007), 1109–1116.
- 322 [27] B. Fagrell, Microcirculatory methods for the clinical assessment of hypertension, hypotension and ischemia, *Annals of*
323 *Biomedical Engineering* **14** (1986), 163–173.
- 324 [28] S. Forconi and T. Gori, Endothelium and hemorheology, *Clin Hemorheol Microcirc* **53** (2013), 3–10.

- 325 [29] U. Forstermann, H. Kleinert, I. Gath, P. Schwarz, E.I. Closs and N.J. Dun, Expression and expressional control of nitric
326 oxide synthases in various cell types, *Advances in Pharmacology* **34** (1995), 171–186.
- 327 [30] C.M. Franco, A.M. Lima, L. Ataíde Jr., O.G. Lins, C.M. Castro, A.A. Bezerra, M.F. de Oliveira and J.R. Oliveira, Obstructive
328 sleep apnea severity correlates with cellular and plasma oxidative stress parameters and affective symptoms, *Journal of*
329 *Molecular Neuroscience* **47** (2012), 300–310.
- 330 [31] A. Ghasemi, S. Zahedi Asl, Y. Mehrabi, N. Saadat and F. Azizi, Serum nitric oxide metabolite levels in a general healthy
331 population: Relation to sex and age, *Life Sciences* **83** (2008), 326–331.
- 332 [32] R. Ginnan, B.J. Guikema, K.E. Halligan, H.A. Singer and D. Jourd'heuil, Regulation of smooth muscle by inducible nitric
333 oxide synthase and NADPH oxidase in vascular proliferative diseases, *Free Radical Biology and Medicine* **44** (2008),
334 1232–1245.
- 335 [33] T. Gori, A. Damaske, S. Muxel, M.C. Radmacher, F. Fasola, S. Schaefer, M. Fineschi, S. Forconi, F. Jung, T. Munzel
336 and J.D. Parker, Endothelial function and hemorheological parameters modulate coronary blood flow in patients without
337 significant coronary artery disease, *Clin Hemorheol Microcirc* **52** (2012), 255–266.
- 338 [34] M.P. Grimaldi, G. Candore, S. Vasto, M. Caruso, G. Caimi, E. Hoffman, G. Colonna-Romano, D. Lio, Y. Shinar, C.
339 Franceschi and C. Caruso, Role of the p53 M694V (A2080G) allele in acute myocardial infarction and longevity: A study
340 in the Sicilian population, *Journal of Leukocyte Biology* **79** (2006), 611–615.
- 341 [35] H. Higashino, H. Miya, H. Mukai and Y. Miya, Serum nitric oxide metabolite (NOx) levels in hypertensive patients at rest:
342 A comparison of age, gender, blood pressure and complications using normotensive controls, *Clinical and Experimental*
343 *Pharmacology and Physiology* **34** (2007), 725–731.
- 344 [36] H. Higashino, M. Tabuchi, S. Yamagata, T. Kurita, H. Miya, H. Mukai and Y. Miya, Serum nitric oxide metabolite levels in
345 groups of patients with various diseases in comparison of healthy control subjects, *Journal of Medical Sciences* **10** (2010),
346 1–11.
- 347 [37] F. Jung, W. Koleyke, S. Spitzer, H. Kiesewetter, K.W. Ruprecht, R. Bach, H. Schieffer and E. Wenzel, Primary and secondary
348 microcirculatory disorders in essential hypertension, *Clinical Investigation* **71** (1993), 132–138.
- 349 [38] K. Kedziora-Kornatowska, J. Czuczejko, H. Pawluk, T. Kornatowski, J. Motyl, L. Szadujkis-Szadurski, K. Szewczyk-Golec
350 and J. Kedziora, The markers of oxidative stress and activity of the antioxidant system in the blood of elderly patients with
351 essential arterial hypertension, *Cellular and Molecular Biology Letters* **9** (2004), 635–641.
- 352 [39] C.A. Kumar and U.N. Das, Lipid peroxides, anti-oxidants and nitric oxide in patients with pre-eclampsia and essential
353 hypertension, *Medical Science Monitor* **6** (2000), 901–907.
- 354 [40] L. Lavie, A. Hefetz, R. Luboshitzky and O. Lavie, Plasma levels of nitric oxide and L-arginine in sleep apnea patients,
355 *Journal of Molecular Neuroscience* **21** (2003), 57–63.
- 356 [41] D. Lio, G. Candore, A. Crivello, L. Scola, G. Colonna-Romano, L. Cavallone, E. Hoffman, M. Caruso, F. Licastro, C.M.
357 Caldarera, A. Branzi, C. Franceschi and C. Caruso, Opposite effects of interleukin 10 common gene polymorphism in
358 cardiovascular diseases and in successful ageing: Genetic background of male centenarians is protective against coronary
359 heart disease, *Journal of Medical Genetics* **41** (2004), 790–794.
- 360 [42] F. Listí, G. Candore, D. Lio, L. Cavallone, G. Colonna-Romano, M. Caruso, E. Hoffman and C. Caruso, Association between
361 platelet endothelial cellular adhesion molecule 1 (PECAM-1/CD31) polymorphism and acute myocardial infarction: A
362 study in patients from Sicily, *European Journal of Immunogenetics* **31** (2004), 175–178.
- 363 [43] F. Listí, G. Candore, D. Lio, M. Russo, G. Colonna-Romano, M. Caruso, E. Hoffman and C. Caruso, Association between
364 C1019T polymorphism of connexin37 and acute myocardial infarction: A study in patients from Sicily, *International*
365 *Journal of Cardiology* **102** (2005), 269–271.
- 366 [44] A. Lopez, A.L. Lorente, J. Steingrub, J. Bakker, A. McLuckie, S. Willatts, M. Brockway, A. Anzueto, L. Holzappel,
367 D. Breen, M.S. Silverman, J. Takala, J. Donaldson, C. Aneson, G. Grove, S. Grossman and R. Grover, Multiple-center,
368 randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in
369 patients with septic shock, *Critical Care Medicine* **32** (2004), 21–30.
- 370 [45] R. Lo Presti, C. Carollo, M. Montana, F. Vaccaro and G. Caimi, Nitric oxide metabolites in chronic renal failure in
371 conservative and in hemodialysis treatment, *Trace Elements and Electrolytes* **25** (2008), 211–212.
- 372 [46] R. Lo Presti, A. Catania, T. D'Amico, M. Montana, M. Caruso and G. Caimi, Oxidative stress in young subjects with acute
373 myocardial infarction: Evaluation at the initial stage and after 12 months, *Clinical and Applied Thrombosis and Hemostasis*
374 **14** (2008), 421–427.
- 375 [47] R. Lo Presti, G. Milio, D. Lucido, G. Amodeo, C. Carollo and G. Caimi, Stress ossidativo in pazienti con sclerodermia:
376 Effetti dell' iloprost, *Minerva Cardioangiologica* **55** (2007), 179–180.

- [48] C.M. Loughrey, I.S. Young, J.H. Lightbody, D. McMaster, P.T. McNamee and E.R. Trimble, Oxidative stress in haemodialysis, *Quarterly Journal of Medicine* **87** (1994), 679–683.
- [49] J.O. Lundberg and M. Govoni, Inorganic nitrate is a possible source for systemic generation of nitric oxide, *Free Radical Biology and Medicine* **37** (2004), 395–400.
- [50] I.M.J. Mackenzie, A. Ekangaki, J.D. Young and C.S. Garrard, Effect of renal function on serum nitrogen oxide concentration, *Clinical Chemistry* **42** (1996), 440–444.
- [51] A. Mazzone, C. Cusa, L. Bucci, M. Vezzoli, S. Ghio, I. Buggia, M.B. Regazzi, G. Fossati, I. Mazzucchelli and D. Gritti, The effect of iloprost infusion on microcirculation is independent of nitric oxide metabolites and endothelin-1 in chronic peripheral ischemia, *European Journal of Clinical Investigation* **29** (1999), 1–5.
- [52] C.J. Menkes, Y. Allanore, D. Borderie, P. Hilliquin, A. Hernvann, O. Ekindjian and A. Kahan, Inducible nitric oxide synthase expression and nitric oxide production by monocytes in systemic sclerosis, *Bulletin de l'Academie Nationale de Medicine* **185** (2001), 509–522.
- [53] T.M. Millar, C.R. Stevens, N. Benjamin, R. Eisenthal, R. Harrison and D.R. Blake, Xanthine oxidoreductase catalyses the reduction of nitrates and nitrite to nitric oxide under hypoxic conditions, *FEBS Letters* **427** (1998), 225–228.
- [54] A. Modin, H. Björne, M. Herulf, K. Alving, E. Weitzberg and J.O. Lundberg, Nitrite derived nitric oxide: A possible mediator of 'acidic-metabolic' vasodilation, *Acta Physiologica Scandinavica* **171** (2001), 9–16.
- [55] M.Y. Mok, P.C.W. Fung, C. Ooi, H.F. Tse, Y. Wong, Y.M. Lam, W.S. Wong and C.S. Lau, Serum nitric oxide metabolites and disease activity in patients with systemic sclerosis, *Clinical Rheumatology* **27** (2008), 315–322.
- [56] S. Moncada, R.M.J. Palmer and E.A. Higgs, Nitric oxide: Physiology, pathophysiology and pharmacology, *Pharmacological Reviews* **43** (1991), 109–142.
- [57] C. Nathan, Inducible nitric oxide synthase: What difference does it make? *Journal of Clinical Investigation* **100** (1997), 2417–2423.
- [58] S.J. Nicholls, Z. Wang, R. Koeth, B. Levison, B. Del Fraino, V. Dzavik, O.W. Griffith, D. Hathaway, J.A. Panza, S.E. Nissen, J.S. Hochman and S.L. Hazen, Metabolic profiling of arginine and nitric oxide pathways predicts hemodynamic abnormalities and mortality in patients with cardiogenic shock after acute myocardial infarction, *Circulation* **116** (2007), 2315–2324.
- [59] M. Olszanecka-Glinianowicz, B. Zahorska-Markiewicz, J. Janowska and A. Zurakowski, Serum concentration of nitric oxide, tumor necrosis factor (TNF)- α and TNF soluble receptors in women overweight and obesity, *Metabolism Clinical and Experimental* **10** (2004), 1268–1273.
- [60] S.M. Ouvina, R.D. La Greca, N.L. Zanaro, L. Palmer and B. Sasseti, Endothelial dysfunction, nitric oxide and platelet activation in hypertensive and diabetic type II patients, *Thrombosis Research* **102** (2001), 107–114.
- [61] J. Oyama, H. Yamamoto, T. Maeda, A. Ito, K. Node and N. Makino, Continuous positive airway pressure therapy improves vascular dysfunction and decreases oxidative stress in patients with the metabolic syndrome and obstructive sleep apnea syndrome, *Clinical Cardiology* **35** (2011), 231–236.
- [62] S. Ozden, S. Tatlipinar, N. Bicer, V. Yaylali, C. Yildirim, D. Ozbay and G. Guner, Basal serum nitric oxide levels in patients with type 2 diabetes mellitus and different stages of retinopathy, *Canadian Journal of Ophthalmology* **38** (2003), 393–396.
- [63] F.O. Pereira, T.S. Frode and Y.S. Medeiros, Evaluation of tumor necrosis alpha, interleukin-2, soluble receptor, nitric oxide metabolites, and lipid as inflammatory markers in type 2 diabetes mellitus, *Mediators of Inflammation* **2006** (2006), 39062.
- [64] M. Saitoh, T. Osanai, T. Kamada, T. Matsunaga, H. Ishizaka, H. Hanada and K. Okumura, High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: Role in reduction of plasma nitric oxide level, *Heart Vessels* **18** (2003), 177–182.
- [65] R. Salem and A. Mebazaa, Nitric oxide inhibition rapidly increases blood pressure with no change in outcome in cardiogenic shock: The TRIUMPH trial, *Critical Care* **11** (2007), 136–137.
- [66] R. Schulz, D. Schmidt, X. Lopes-Ribeiro, C. Lucke, K. Mayer, H. Olschewski, W. Seeger and F. Grimminger, Decrease plasma levels of nitric oxide derivatives in obstructive sleep apnoea: Response to cPAP therapy, *Thorax* **55** (2000), 1046–1051.
- [67] A. Sud, M. Khullar, A. Wanchu and P. Bamberg, Increased nitric oxide production in patients with systemic sclerosis, *Nitric Oxide* **4** (2000), 615–619.
- [68] R.H. Surekha, B.B.M.V. Srikanth, P. Jharna, R.V. Ramachandra, R.V. Dayasagar and A. Jyothy, Oxidative stress and total antioxidant status in myocardial infarction, *Singapore Medicine* **48** (2007), 137–142.
- [69] K. Takagi, Y. Kawaguchi, M. Hara, T. Sugiura, M. Harigai and N. Kamatani, Serum nitric oxide (NO) levels in systemic sclerosis patients: Correlation between NO levels and clinical features, *Clinical and Experimental Immunology* **134** (2003), 538–544.

- 430 [70] The Triumph Writing Committee, Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic
431 shock. The TRIUMPH randomized controlled trial, *JAMA* **297** (2007), 1657–1666.
- 432 [71] P. Ulker, F. Gunduz, H.J. Meiselman and O.K. Baskurt, Nitric oxide generated by red blood cells following exposure to shear
433 stress dilates isolated small mesenteric arteries under hypoxic condition, *Clinical Hemorheology and Microcirculation*, in
434 press.
- 435 [72] P. Ulker, L. Sati, C. Celik-Ozenci, H.J. Meiselman and O.K. Baskurt, Mechanical stimulation of nitric oxide synthesizing
436 mechanisms in erythrocytes, *Biorheology* **46** (2009), 121–132.
- 437 [73] P. Ulker, N. Yaras, O. Yalcin, C. Celik-Ozenci, P.C. Johnson, H.J. Meiselman and O.K. Baskurt, Shear stress activation
438 of nitric oxide synthase and increased nitric oxide levels in human red blood cell, *Nitric Oxide-Biology and Chemistry* **24**
439 (2011), 184–191.
- 440 [74] T. Vyzantiadis, A. Karagiannis, S. Douma, P. Harsoulis, A. Vyzantiadis and C. Zamboulis, Vascular endothelial growth
441 factor and nitric oxide serum levels in arterial hypertension, *Clinical and Experimental Hypertension* **28** (2006), 603–609.
- 442 [75] J.B. Weinberg, Nitric oxide production and nitric oxide synthases type 2 expression by human mononuclear phagocytes –
443 a review, *Molecular Medicine* **4** (1998), 557–591.
- 444 [76] S.M. Wildhirt, R.R. Dudek, H. Suzuki, and R.J. Bing, Involvement of inducible nitric oxide synthase in the inflammatory
445 process of myocardial infarction, *International Journal of Cardiology* **50** (1995), 253–261.
- 446 [77] T. Yamamoto, I. Katayama and K. Nishioka, Nitric oxide production and inducible nitric oxide synthase expression in
447 systemic sclerosis, *Journal of Rheumatology* **25** (1998), 314–317.
- 448 [78] J.W. Yoon, M.V. Pahl and N.D. Vaziri, Spontaneous leukocyte activation and oxygen-free radical generation in end-stage
449 renal disease, *Kidney International* **71** (2007), 167–172.
- 450 [79] I. Zavaroni, D. Ardigo, P.C. Rossi, A. Zuccarelli, E. Pacetti, L. Monti, P.M. Piatti and G.M. Reaven, Relationship between
451 plasma nitric oxide concentration and insulin resistance in essential hypertension, *American Journal of Hypertension* **17**
452 (2004), 549–552.
- 453 [80] D.L. Zhang, H. Liao, Y.Y. Wei, Y. Zhang, Q.D. Zhang and Z.G. Wang, Elevation in serum apelin-13 is positively correlated
454 with ADMA in patients on maintenance hemodialysis, *Clinical Nephrology* **71** (2009), 405–412.